ArticleFrontiers in immunology2026
Integrated transcriptomic profiling reveals immune and molecular stage-specific signatures of colorectal cancer in hispanics living in Puerto Rico.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colorectal cancer (CRC) remains one of the most diagnosed malignancies worldwide and continues to rank among the leading causes of cancer-related death. Cancer progression involves dynamic transcriptional and immunological changes, and although many key molecular alterations driving CRC progression have been described, stage-specific differences remain poorly understood. This study aimed to characterize transcriptomic changes in Hispanics living in Puerto Rico (PRH) to identify relevant pathways, target genes, and stage-specific immune and molecular signatures. Methods: We conducted RNA sequencing (RNA-seq) from colorectal tissues, including early-stage CRC (stages I & II), advanced-stage CRC (stage III only), and adjacent mucosal tissue, to elucidate key mechanisms that modulate CRC progression. Results: Transcriptomic analysis revealed distinct gene expression patterns across stages, with a total of 1666 and 1955 differentially expressed genes at early and advanced stages, respectively. Early-stage CRC was significantly enriched for biological pathways associated with immune regulation, including cytokine signaling, epithelial barrier function, and tissue repair mechanisms, reflected in part by activation of components of the Wnt signaling pathway. In contrast, advanced-stage (stage III) CRC displayed immunosuppressive transcriptional profiles and activation of tumor-promoting pathways, including TNF signaling, enhancement of IL-17 and Wnt signaling pathways, NF-κB signaling, angiogenesis, epithelial-mesenchymal transition (EMT), and stromal remodeling. Discussion: Pathway enrichment analyses supported a shift from immune engagement and matrix remodeling in early CRC to immune evasion and pro-metastatic programs in advanced-stage disease (comprised of stage III; metastatic stage IV was not sampled). While Wnt signaling components were differentially expressed across stages, they appeared as part of a broader network of developmental and inflammatory signals driving progression. This study provides preliminary transcriptomic evidence to inform stage-specific biomarker discovery in PRH CRC that warrants further validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.